Management of Patients with ST-Segment Elevation Myocardial Infarction during the COVID-19 Pandemic

Objective: Elective operations had to be postponed due to the COVID-19 pandemic that emerged in the last quarter of 2019 and affected the whole world in a short time. However, for emergencies such as myocardial infarction (MI), unfortunately, this is not possible. We aimed to evaluate the management of ST-segment elevation myocardial infarction (STEMI) before and during the COVID-19 pandemic. Methods: One hundred and eleven consecutive patients with STEMI between April 2020 and May 2020 and 149 patients with STEMI 1 year before the pandemic in the same period were included in the study. Groups were compared in terms of the treatments applied, pre–post-dilatation, duration of the procedure, hospitalization, and the primary end-point. Death due to MI or complications of MI was the primary end-point. Results: The mean age of the patients was 59.7 6 12.3 (n ¼ 195 [75%] male). The two groups were similar in terms of gender, diabetes mellitus, hypertension, hyperlipidemia, smoking, and laboratory results. Although the median duration of the door balloon in the pandemic was similar (39 and 37minutes, respectively; P ¼ .342), the procedure times were shorter, the mean total hospitalization times were longer, and the differences were statistically significant (P ¼ .022 and

PDF

___

1. Schiavone M, Gobbi C, Biondi-Zoccai G, et al. Acute coronary syndromes and COVID-19: Exploring the uncertainties. JCM. 2020;9:1683. [CrossRef]
2. Sheth AR, Grewal US, Patel HP, et al. Possible mechanisms responsible for acute coronary events in COVID-19. Med Hypotheses. 2020;143:110125. [CrossRef]
3. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: The pathologists’ view. Eur Heart J. 2013;34:719-728. [CrossRef]
4. Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, part I. Mayo Clin Proc. 2009;84:917-938. [CrossRef]
5. Kristensen SD, Andersen HR, Thuesen L, et al. Should patients with acute ST elevation MI be transferred for primary PCI? Heart. 2004;90:1358-1363. [CrossRef]
6. Ibanez B, James S. The 2017 ESC STEMI guidelines. Eur Heart J. 2018;39:79-82. [CrossRef]
7. Li YH, Wang MT, Huang WC, Hwang JJ. Management of acute coronary syndrome in patients with suspected or confirmed coronavirus disease 2019: Consensus from Taiwan Society of Cardiology. J Formosan Med Assoc. 2021;120(1):78-82.
8. Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020;56:106024. [CrossRef]
9. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-260. [CrossRef]
10. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17:543-558. [CrossRef]
11. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19- related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17:1463-1471. [CrossRef]
12. Harikrishnan S, Mohanan PP, Chopra VK, et al. Cardiological society of India position statement on COVID-19 and heart failure. Indian Heart J. 2020;72:75-81. [CrossRef]
13. Hosseiny AD, Doost A, Moloi S, Chandrasekhar J, Farshid A. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. Open Heart. 2016;3:E000405. [CrossRef]
14. Lee JM, Hwang D, Park J, Kim KJ, Ahn C, Koo BK. Percutaneous coronary intervention at centers with and without on-site surgical backup an updated meta-analysis of 23 studies. Circulation. 2015;132:388-401. [CrossRef]
15. Vejpongsa P, Kitkungvan D, Madjid M, et al. Outcomes of acute myocardial infarction in patients with influenza and other viral respiratory infections. Am J Med. 2019;132:1173-1181. [CrossRef]
16. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: A meta-analysis of case-control studies. Heart. 2015;101(21):1738-1747. [Cross- Ref]
17. Secco GG, Tarantini G, Mazzarotto P, et al. Invasive strategy for COVID patients presenting with acute coronary syndrome: The first multicenter Italian experience. Catheter Cardiovasc Interv. 2021;97:195-194. [CrossRef]
18. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531-538. [CrossRef]
19. Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C. Management of acute myocardial infarction during the COVID- 19 pandemic a position statement from the society for cardiovascular angiography and interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). JACC. 2020;76:1375-1384. [CrossRef]
20. Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81:357-371. [CrossRef]
21. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet North Am Ed. 2003;361(9371):1767-1772. [CrossRef]